View Post

Inbiomotion’s MAF Test® selects breast cancer patients benefitting from adjuvant clodronate, significantly improving their overall survival

In Clinical Studies News by Barbara Jacoby

Source: Inbiomotion From: – Level 1 evidence from the MAF Test® analyses of the NSABP-B34 landmark clinical trial confirmed clinical utility of the MAF Test® for selection of early-stage breast cancer patients that benefit from adjuvant clodronate treatment to prevent metastasis – Data published in Journal of National Cancer Institute, Cancer Spectrum – MAF-negative status of patients who were …